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Overview of Tumor Promotion in Animals
by T. J. Slaga*
Our present understanding of two-stage carcinogenesis encompasses almost four decades of re-
search. Evidence for chemical promotion or cocarcinogenesis was first provided by Berenblum, who
reported that a regimen of croton oil (weak or noncarcinogenic) applied alternately with small doses
of benzo(a)pyrene (BP) to mouse skin induced a larger number of tumors than BP alone. Subse-
quently, Moltram found that a single subcarcinogenic dose of BP followed by multiple applications
of croton oil could induce a large number of skin tumors. These investigations as well as a number
of others, such as Boutwell, Van Duuren and Hecker, were responsible in defining many important
aspects of the initiation and promotion of two-stage carcinogenesis. The initiation stage in mouse
skin requires only a single application of either a direct-acting carcinogen or a procarcinogen and is
essentially an irreversible step which as data suggests probably involves a somatic cell mutation.
The promotion stage in mouse skin can be accomplished by a wide variety of weak or noncarcino-
genic agents and is initially reversible later becoming irreversible. Current information suggests
that skin tumor promoters are not mutagenic but bring about a number of important epigenetic
changes, such as epidermal hyperplasia, and an increase in polyamines, prostaglandins and dark
basal keratinocytes as well as other embryonic conditions. Recently, tumor promotion in mouse skin
was shown to consist of at least two stages, in which each stage can be accomplished by either a
known promoter or a weak or nonpromoting agent. Some of the important characteristics of the
first stage of promotion are: (1) only one application of a first-stage promoter, such as phorbol ester
tumor promoters, calcium ionophore A23187, hydrogen peroxide and wounding is needed; (2) the ac-
tion is partially irreversible; (3) an increase in dark basal keratinocytes and prostaglandins is im-
portant; and (4) such an increase can be inhibited by antiinflammatory steroids and protease inhibi-
tors. The second stage of promotion is initially reversible but later becomes irreversible. Poly-
amines and epidermal cell proliferation are important events in the second stage of promotion. A
number of weak or nonpromoting agents, such as mezerein, are effective second-stage promoters
which can be counteracted by retinoic acid, antiinflammatory steroids and polyamine synthesis in-
hibitors. Although skin tumor promotion has been extensively studied in mice, not all strains and
stocks of mice are susceptible to phorbol ester tumor promoters. In this regard, the C57BL/6 mice
appear to be fairly resistant to phorbol ester tumor promoters. In addition, not all species are
equally susceptible to phorbol ester tumor promotion.
Recently the generality of the two-stage system of inducing tumors has been shown to exist in a
number of experimental carcinogenesis systems, such as the liver, bladder, lung, colon, esophagus,
stomach, mammary gland, pancreas and cells in culture. In these systems, a wide variety of pro-
moting agents such as diet, bile acids, hormones, saccharin, tryptophan, phenobarbital, polychlo-
rinated biphenyls, polybrominated biphenyls and butylated hydroxytoluene have been used to ac-
complish the tumor promotion stage. It is not presently known if other experimental carcinogenesis
systems and the induction of human cancer involves a series of stages similar to that in the mouse
skin.
Introduction
Our present understanding of two-stage carcino-
genesis encompasses almost four decades of re-
search. Skin carcinogenesis has been known to oc-
cur by a two-stage process since Rous and co-
workers reported the enhancing effect of irritation
on the process of tumor formation. (1). Evidence for
chemical promotion or cocarcinogenesis was first
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provided by Berenblum who reported that a regi-
men of croton oil (weak or noncarcinogenic) applied
alternately with small doses of benzo(a)pyrene (BP)
to mouse skin induced a larger number of tumors
than BP alone (2). Subsequently, Mottram (3)found
that a single subcarcinogenic dose ofBP followed by
multiple applications of croton oil could induce a
large number of skin tumors. These investigators,
as well as a number of others, including Boutwell,
Van Duuren and Hecker (47), were responsible for
defining many important aspects of the initiation
and promotion oftwo-stage carcinogenesis.T. J. SLAGA
The characteristics of two-stage carcinogenesis in
mouse skin are illustrated in Figure 1. Skin tumors
can be induced by the sequential application of a
subthreshold dose of a carcinogen (initiation stage)
followed by repetitive treatment with a noncarcino-
genic promoter (promotion stage). The initiation
phase requires only a single application of either a
direct or an indirect carcinogen and is essentially an
irreversible step, while the promotion phase is ini-
tially reversible later becoming irreversible. As
shown in Figure 1, a single large dose of a carcino-
gen such as 7,12-dimethylbenz(a)anthracene
(DMBA) is capable of inducing skin tumors in mice.
Papillomas occurred after a relatively short latency
period (10 to 20 weeks), with carcinomas developing
after a much longer period (20-60 weeks). If this
dose was lowered as shown in Number 2 of Figure
1, it became necessary to administer DMBA repeat-
edly in order to induce tumors. If progressively re-
duced, a subthreshold dose of DMBA was reached
which did not give rise to tumors over the lifespan
of the mouse. If either croton oil or a phorbol ester
such as 12-O-tetradecanoylphorbol-13-acetate (TPA)
was subsequently applied repetitively to the backs
of mice previously initiated with a single subthresh-
old dose of DMBA, multiple papillomas appeared
after a short latency period, followed by squamous
cell carcinomas after a much longer period. The re-
petitive application of the promoter without initia-
tion by DMBA in general either does not give rise
to tumors or produces only a few, and a dose-re-
sponse relationship is never shown (8). If the mice
are initiated with a subthreshold dose of a carcino-
gen such as DMBA, there is an excellent dose re-
sponse with TPA as the promoter (8). Likewise,
there is a very good dose response with BP or
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FIGURE 1. Diagram of two-stage carcinogenesis.
DMBA as a tumor initiator when the promoter dose
is held constant (8). Also shown in Figure 1 is the
importance of the order of treatments of the initia-
tor and promoter. If repetitive applications of the
promoter are administered before initiation, no tu-
mors will develop. The real hallmark of the two-
stage carcinogenesis system in mouse skin relates
to the irreversibility of tumor initiation. A lapse of
up to one year between the application of the
initiator and the beginning of the promoter treat-
ment provides a tumor response similar to that ob-
served when the promoter is given only one week
following initiation (4). Unlike the initiation phase,
the promotion stage is reversible, requiring a cer-
tain frequency of application in order to induce tu-
mors (4). Burns and co-workers have reported re-
sults which suggest that there is a progression of
certain autonomous papillomas to squamous cell car-
cinomas, whereas some papillomas are tumor pro-
moter-dependent (9). Also (Fig. 1), tumor promotion
has been shown to be divided into at least two
stages (10). The multistage nature of tumor promo-
tion in mouse skin will be described in detail later.
Until recently one of the major criticisms of the
two-stage carcinogenesis system was its uniqueness
to mouse skin and the fact that it was not opera-
tional in other tissues and in other species. How-
ever, recently the generality of the two-stage sys-
tem of carcinogenesis has been shown to exist in a
number of systems other than the skin such as the
liver, lung, bladder, colon, esophagus, mammary
gland, stomach, esophagus, pancreas and cells in cul-
ture (11). Table 1 summarizes the various agents
found to have enhancing and/or promoting activity
in other organs.
Table 1. Tumor promoters and/or enhancing agency for
tissues other than the skin.a
Organ system Agent
Liver Phenobarbital, DDT, BHT, PCB,
TCDD, phorbol, thioacet-
amide, a-hexachlorocyclo-
hexane
Lung BHT, phorbol
Colon Bile acids, high fatdiet, high
cholesterol diet
Bladder Saccharin, cyclamate,
tryptophan
Mammary gland Hormones, high fat diet, phorbol
Stomach and forestomach Surfactant, TPA, salt
Esophagus Diet, alcohol and smoking
Pancreas Diet, smoking
Mouse cell culture systems Phorbol esters, saccharin
Rat tracheal organ
culture system Phorbol esters
aSee Slaga et al. (11) for individual references.
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Complete and Two-Stage Carcino-
genesis in Different Species and
Stocks and Strains of Mice
In general, as shown in Table 2, mice are more
sensitive to skin carcinogenesis by either the com-
plete carcinogenesis protocol or by the initiation-
promotion protocol than rats and hamsters (11, 12).
The complete carcinogenesis protocol in mice gives
rise to a low number of papillomas followed by a
high incidence of squamous cell carcinomas, where-
as the initiation-promotion protocol gives rise to a
large number of papillomas followed by a high inci-
dence of squamous cell carcinomas. Both the com-
plete carcinogenesis and initiation-promotion proto-
cols in rats gives rise to basal cell carcinomas and
very few papillomas and squamous cell carcinomas.
The complete carcinogenesis protocol in hamsters
produces mainly squamous cell carcinomas and
some melanomas, whereas the initiation-promotion
protocol produces mainly melanomas.
The SENCAR stock of mice was selectively bred
for sensitivity to skin tumor induction by DMBA
initiation followed by TPA promotion (12). Conse-
quently, the SENCAR mouse is extremely sensitive
to two-stage carcinogenesis and coincidentally sensi-
tive to complete carcinogenesis (12). However, there
exist several other stocks and strains of mice that
are refractory to promotion or differ in their suscep-
tibility to complete and two-stage carcinogenesis
(12). Table 3 ranks the susceptibility of several
mouse strains and stocks to complete and two-stage
carcinogenesis. It is important to emphasize the lim-
itations of these rankings. Firstly, only the re-
sponses to BP and DMBA were included in the anal-
yses. Secondly, dose-response data for both the car-
cinogen and/or promoter were not available for
many of the mouse strains and stocks. Although
these rankings represent subjective analyses, the
differences between mice on the extremes of the
rankings are significant.
Tumor Initiation
Whenever a known skin carcinogen has been
appropriately tested, it has shown skin tumor-initi-
ating activity (8). In a two-stage mouse skin system,
initiation is the only stage that requires the pres-
ence of the carcinogen and the measured carcino-
genic potency of a chemical reflects its capacity for
tumor initiation. There is both a good qualitative
and quantitative correlation between the complete
carcinogenic and tumor initiating activities of sev-
eral chemical carcinogens in mouse skin (8). This is
true when one considers the number of papillomas
per mouse at early times (10 to 20 weeks) or the
final carcinoma incidence after tumor initiation (8).
It is possible that a carcinogen lacking promoting
ability would not be detected when tested as a com-
plete carcinogen. In this regard, however, we have
found a number of chemical compounds such as
benz(a)anthracene (BA), dibenz(a,c)anthracene,
[DB(a,c)A], chrysene, urethan, BP-7,8-dihydrodiol-
9,10-epoxide and BA-3,4-dihydrodiol-1,2-epoxide that
have tumor-initiating activity but either lack or
have very weak complete carcinogenic activity (8).
There is a good dose-response relationship of
many carcinogens used as tumor initiators in the
two-stage carcinogenesis system using SENCAR
Table 2. Comparison of complete carcinogenesis and initiation-promotion in various species.a
Tumor histology
Basal cell No. of
Species Treatment carcinomas Carcinomas papillomas Melanomas
Mouse Complete + + +
Two-stage + + + + +
Rat Complete +
Two-stage +
Hamster Complete + +
Two-stage +
aData ofSlaga (12) and Phillips et. al. (20).
Table 3. Sensitivity to skin carcinogenesis in different stocks and strains of mice.a
Action Order ofsensitivity
Complete carcinogenesis SENCAR>CD-1>C57BL/6>BALB/c>ICR/Ha Swiss>C3H
Two-stage carcinogenesis SENCAR>>CD-1>ICR/Ha Swiss>BALB/c>C57BL/6>C3H >DBA/2
(initiation-promotion)
aData represent sensitivities to BP and DMBA. Rankings represent a subjective analysis because dose-response data were not
available for many strains (12,20).
5mice. This is illustrated in Table 4. A good dose-re-
sponse relationship exists for DMBA and BP to ini-
tiate skin tumors in Sencar mice. As can be seen, a
good correlation exists between the number of pap-
illomas per mouse at 15 weeks and the final carcino-
mas incidenced at 50 weeks. The percent of mice
with papillomas has also a reasonable correlation
but the dose response is very narrow. The Sencar
mouse was derived from crossing Charles River CD-
1 mice with skin tumor sensitive mice (originally de-
rived from Rockland mice) and selecting for sensi-
tivity to DMBA-phorbol ester tumor promoter two-
stage carcinogenesis for eight generations starting
with the F1 cross as described by Boutwell (4). The
mice developing the earliest and most papillomas
after initiation-promotion treatment were selected
for each breeding. The Sencar mice are between 10
and 20 times more sensitive to DMBA tumor initia-
tion than the CD-1 mice (13). However, the SEN-
CAR mice are only between three and five times
more sensitive to BP tumor initiation than the CD-1
mice (13). In addition, the Sencar mice are two to
three times more sensitive to TPA promotion than
the CD-1 (13).
There is even a greater difference in the sensitiv-
ity to two-stage skin carcinogenesis between Sencar
and C57BL/6 mice. As pointed out above, the Sencar
mouse is very sensitive to two-stage and complete
carcinogenesis. C57BL/6 mice are very refractory to
two-stage skin carcinogenesis by BP-TPA. As
shown in Table 5, even high initiating doses of BP
(1600 nmole) and high promoting doses of TPA (10
,g) are very ineffective in causing skin tumors (12).
However, C57BL/6 mice do respond to complete car-
cinogenesis by BP (10). This unequal susceptibility
to complete and two-stage carcinogenesis within a
stock or strain of mice strongly suggests that the
promotional phases of complete and two-stage carci-
nogenesis are dissimilar. In addition, differences in
sensitivity to initiation and promotion between mice
may be due to alterations in the promotional phase
of two-stage carcinogenesis. In this regard, we have
recently found that benzoyl peroxide is an effective
promoter in C57BL/6 and Sencar mice (Slaga et al.,
unpublished data). The reason why TPA is not an
effective promoter in C57BL/6 mice may be related
to its lack of ability to induce a sustained hyper-
plasia (Davidson and Slaga, unpublished data).
The tumor initiation phase appears to be an irre-
versible step which probably involves a somatic cell
Table 4. Dose-response studies on the ability of DMBA and BP to initiate skin tumors in SENCAR mice.a
No. of papillomas % of mice % of mice
Dose, per mouse with papillomas with carcinomas
Initiator nmole at 15 weeks at 15 weeks at 50 weeks
DMBA 100 22.0 100 100
DMBA 10 6.8 100 40
DMBA 1 3.2 93 22
DMBA 0.1 0.5 20 5
BP 200 7.5 100 55
BP 100 3.2 78 30
BP 50 1.4 60 18
aThe mice were treated 1 week after initiation with twice weekly applications of 5 .g of TPA (8).
Table 5. Initiation-promotion in SENCAR and C57BL/6 mice.
Treatment Animal Result Dose response
TPA, repetitive, 52 SENCAR 5-20% papillomas No
weeks, no initiation mouse <15% carcinomas
Benzoyl peroxide, SENCAR <5% tumors No
repetitive, 52 weeks, mouse
no initiation
TPA, 52 weeks, SENCAR Papillomas (early) Yes
after initiation mouse Carcinomas (late)
Benzoyl peroxide SENCAR Papillomas (early) Yes
after initiation mouse Carcinomas (late)
TPA, repetitive, 52 C57BL/6 None
weeks, no initiation mouse
Benzoyl peroxide, repetitive C57BL/6 None
52 weeks, no initiation mouse
TPA, repetitive, 52 weeks, C57BL/6 <5% papillomas
initiation with 50-1600 nmole BP mouse <10% carcinomas
Benzoyl peroxide, repetitive, 52 C57BL/6 45% carcinomas
weeks, after initiation mouse
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mutation as evidenced by a good correlation be-
tween the carcinogenicity of many chemical carcino-
gens and their mutagenic activities (14-16). Most tu-
mor initiating agents either generate or are meta-
bolically converted to electrophilic reactants, which
bind covalently to cellular DNA and other macro-
molecules (16). Previous studies have demonstrated
a good correlation between the carcinogenicity of
several polycyclic aromatic hydrocarbon (PAH) and
their ability to bind covalently (8,17,18). Table 6
summarizes our data which shows the strong corre-
lation between the covalent binding of PAH to
DNA and their tumor initiating activities.
As previously discussed, for any individual stock
or strain of mouse, it has been generally observed
that there is an excellent correlation between the
amount of PAH bound to DNA and the skin tumor
response. However, this correlation between DNA
binding and tumor response breaks down when a
comparison is made between mouse strains or
stocks that differ in their tumor response to two-
stage or to complete carcinogenesis (19,20). Phillips
et al. (19,20) have demonstrated that the kinetics of
binding of DMBA to the DNAs of C57BL/6, DBA/2
and Swiss mice were virtually identical. Although
there is the possibility that a specific metabolite of
the DMBA was responsible for the tumor response
and was undetected in this study, recent investiga-
tions suggest that the major metabolites of DMBA
and BP are qualitatively similar in mouse strains
that vary in their response to two-stage or complete
carcinogenesis with PAHs (13). Although these data
are far from conclusive, they suggest that some as-
pects of initiation are probably similar in strains of
mice that differ in their response to two-stage or
complete carcinogenesis.
Inhibitors of Tumor Initiation
In order to help us better understand the mecha-
nism of PAH carcinogenesis, we have been studying
many compounds with the capacity to inhibit PAH
Table 6. Correlation of ability of polycyclic aromatic
hydrocarbons (PAHs) to bind covalently to epidermal DNA with
the tumor initiating activity.a
Relative ability
to covalently bind Relative tumor
PAHs to epidermal DNA initiating activity
DMBA 10.0 10.0
MC 6.5 6.0
BP 3.3 2.0
DB(a,h)A 1.7 1.5
DB(a,c)A 0.8 0.2
aDMBA was given a value of 10 since it gave the maximum
response in binding and to initiate tumors in a two-stage
system of tumorigenesis. All the other PAHs are expressed
as values relative to DMBA's response.
tumor initiation. Potent inhibitors of skin tumor ini-
tiation in mice include: antioxidants [butylated hy-
droxytoluene (BHT), butylated hydroxyanisole
(BHA) and selenium], flavones (7,8-benzoflavone, 5,6-
benzoflavone and quercetin) vitamins A, C and E;
certain noncarcinogenic polycyclic aromatic hy-
drocarbons [dibenz(a,c)anthracene, benz(a)anthra-
cene, benzo(e)pyrene and pyrene]; environmental
contaminants such as 2,3,7,8-tetrachlorodibenzo-p-di-
oxin (TCDD) and polychlorobiphenyls (PCB); sulfur
mustard; polyriboinosinic-polyribocytidylic acid
(Poly I:C); and anti-inflammatory steroid.
Some of the flavones and antioxidants appear to
inhibit skin carcinogenesis by inhibiting the metabo-
lism of the carcinogen to its ultimate carcinogenic
form (21,22). The antioxidants, butylated hydroxyan-
isole (BHA) and butylated hydroxytoluene (BHT),
are widely used as food preservatives and have
been shown to also inhibit lung, mammary, fore-
stomach, colon and liver cancer in experimental ani-
mals induced by a wide range of chemicals (23). Sim-
ilar inhibitory results have been noted for selenium
and vitamins C and E (8,21). The noncarcinogenic
PAHs and the environmental contaminants appear
to inhibit skin carcinogenesis by inducing the me-
tabolism of the carcinogen to detoxified products,
thereby decreasing the binding of the PAH to DNA
(24,25). This is epitomized by the environmental
contaminants 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) and polychlorobiphenyls (PCB) which are
extremely potent inducers of PAH carcinogen me-
tabolism and potent inhibitors of their carcinogenic
effect (26-28). Although TCDD is one of the most
toxic agents known, its inhibitory effect on PAH
carcinogenesis is at nontoxic dose levels.
Sulfur mustard inhibits tumor initiation by actual-
ly killing the initiated cells (29). The polyinosinic:-
polycytidylic acid(Poly I:C) and the anti-inflamma-
tory steroids appear to inhibit tumor initiation by
slowing down carcinogen metabolism by their
antigrowth effect (30,31). Some of the above agents
have been shown to inhibit carcinogenesis in a
number of tissues and by a variety of chemical car-
cinogens, indicating they may be useful agents in
the chemoprevention of cancer in man (23). In gen-
eral, these inhibitors of skin tumor initiation act by
(1) alteration of the metabolism of the carcinogen
(decreased activation and/or increased detoxifica-
tion), (2) scavenging of active molecular species of
carcinogens to prevent their reaching the critical
target site(s) in the cells or (3) competitive inhibi-
tion. In all cases this leads to a decrease in covalent
binding to critical targets such as DNA. Table 7 re-
veals a good correlation in SENCAR or CD-i mice
between the ability of a number of compounds to in-
hibit tumorigenesis and their ability to inhibit the
binding of the PAH to DNA.T. J. SLAGA
Tumor Promotion
Although the phorbol esters are the most potent
of the mouse skin tumor promoters, a wide variety
of other compounds have been shown to have skin
tumor promoting activity, as shown in Table 8.
After the phorbol esters and dihydroteleocidin B,
anthralin is the most potent tumor promoter known
of the compounds listed in Table 8. Van Duuren and
co-workers have reported a fairly extensive struc-
ture-activity study with anthralin and derivatives
(32). Likewise, Boutwell and co-workers (33) have re-
ported a structure-activity study of a number of
phenolic compounds which are weak promoters in
comparison to the phorbol esters and anthralin. Al-
though several of the other compounds shown in
Table 8 have moderate to weak activity as tumor
promoters there have not been any extensive struc-
ture-activity studies performed. We have recently
found that benzo(e)pyrene (25) and benzoyl peroxide
(34) are relatively good tumor promoters. In addi-
tion, Scribner and Scribner (35) reported that the
moderate complete carcinogenic activity of 7-bromo-
methylbenz(a)anthracene was due to its strong pro-
Table 7. Correlation of various compounds to inhibit tumor
initiation by DMBA with their abilities to inhibit covalent
binding of DMBA to epidermal DNA.a
Relative ability Relative ability to
to inhibit DMBA inhibit DMBA
tumor initiation binding to by at
Inhibitors by at least 50% least 50%
TCDD 100.0 100.0
DB(a,c)A 10.0 15.0
7,8-BF 5.0 8.0
B(e)P 5.0 3.0
BHA 0.2 0.1
BHT 0.1 0.1
Vitamin C 0.1 0.1
aTCDD was given a value of 100 since it gave the greatest
inhibition of tumor initiation and DMBA binding to epidermal
DNA. For example, TCDD at a 1 ,mg dose level almost com-
pletely inhibited DMBA tumorigenesis and DMBA binding to
DNA. All the other compounds are expressed as values
relative to TCDD's response. For example, BHA at a 1000 Ag
dose level inhibited DMBA tumor initiation and binding by at
least 50%.
moting activity and weak initiating activity. Other
free radical-generating compounds which are good
skin tumor promoters include benzoyl peroxide,
lauroyl peroxide, decanoyl peroxide, chloroperben-
zoic acid, p-nitroperoxybenzoic acid and tert-butyl
hydroperoxide. These agents were found not to
have skin tumor initiating or complete carcinogenic
activity (34).
The dose-response ability of TPA to promote tu-
mors after DMBA initiation is shown in Table 9. As
was the case for tumor initiation, there is also a
very good dose-response relationship for tumor
promotion when considering either the number of
papillomas per mouse at 15 weeks or the percent of
mice with squamous cell carcinomas at 50 weeks.
Similar results have also been reported using
SENCAR mice (36), Charles River CD-1 mice (37) or
ICR/Ha Swiss mice (38).
In addition to causing inflammation and epider-
mal hyperplasia, the phorbol ester and other tumor
promoters produce several other morphological and
biochemical changes in skin as listed in Table 10. Of
Table 8. Skin tumor promoters.a
Promoters Potency
Croton oil Strong
Certain phorbol esters found in croton oil Strong
Some synthetic phorbol esters Strong
Certain euphorbia latices Strong
Anthralin Moderate
Certain fatty acids and fatty acid methyl esters Weak
Certain long chain alkanes Weak
Phenolic compounds Weak
Surface active agents (sodium lauryl sulfate, Weak
tween 60)
Citrus oils Weak
Extracts of unburned tobacco Moderate
Tobacco smoke condensate Moderate
Iodoacetic acid Weak
1-fluoro-2,4-dinitrobenzene Moderate
Benzo(e)pyrene Moderate
Benzoyl peroxide Moderate
7-Bromoethylbenz(a)anthracene Strong
Dihydroteleocidin B Strongb
aData of Slaga (8).
bDihydroteleocidin B has promoting activity at doses
similar to TPA (Slaga and Sugimura, unpublished data).
Table 9. Dose-response studies on the ability of TPA to promote tumors after DMBA initiation.a
Time to first No. of papillomas % %
Dose, papilloma, per mouse with papillomas with carcinomas
Promoter j.g weeks at 15 weeks at 15 weeks at 50 weeks
TPA 10 8 3.0 100 32
TPA 5 6 7.2 100 46
TPA 2 7 6.5 100 45
TPA 1 8 3.6 80 25
TPA 0.1 11 0.4 5 8
aThe mice were initiated with 10 nmole of DMBA and promoted one week later with twice weekly applications of various dose
levels of TPA (12).
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Table 10. Morphological and biochemical responses of mouse
skin to phorbol ester and other tumor promoters.a
Response
* Induction of inflammation and hyperplasia
Increase in DNA, RNA and protein synthesis
Initial increase in keratinization followed by a decrease
Increase in phospholipid synthesis
Increase in prostaglandin synthesis
Increase in histone synthesis and phosphorylation
* Increase in ornithine decarboxylase activity followed by
increase in polyamines
Increase in histidine and DOPA decarboxylase activityb
Decrease in the isoproterenol stimulation of cAMP
Decrease in the number of dexamethasone receptorsb
Decrease in SOD and catalaseb
* Induction of embryonic state in adult skin
* 1. Induction of dark cells (primitive stem cells)
2. Induction of embryonic proteins in adult skin
3. Induction of morphological changes in adult skin
resembling papillomas, carcinomas and embryonic
skin
4. Decrease in histidase activity
5. Increase in protease activity
6. Decrease in response ofGichalone in adult skin
7. Increase in cAMP independent protein kinase in adult
skin resembling tumors and embryonic skin
aSee Slaga et al. (55).
bSlaga et al., unpublished results.
the observed phorbol ester related effects on the
skin, the induction of epidermal cell proliferation, or-
nithine decarboxylase (ODC) and dark basal keratin-
ocytes have the best correlation with promoting ac-
tivity (39-44). In addition to the induction of dark
cells, which are normally present in large numbers
in embryonic skin, there are many other embryonic
conditions which appear in adult skin after treat-
ment with tumor promoters (Table 10).
It is difficult to determine which of the many ef-
fects associated with phorbol ester tumor promo-
tion are in fact essential components of the promo-
tion process. A good correlation appears to exist be-
tween promotion and epidermal hyperplasia when
induced by phorbol esters (40). However, other
agents that induce epidermal cell proliferation do.
not necessarily promote carcinogenesis (45). How-
ever, it should be emphasized that all known skin
tumor promoters do induce epidemal hyperplasia
(11). O'Brien et al. (39) have reported an excellent
correlation between the tumor promoting ability of
various compounds (phorbol esters as well as non-
phorbol ester compounds) and their ability to induce
ODC activity in mouse skin. However, mezerein, a
diterpene similar to TPA but with weak promoting
activity, was found to induce ODC to levels that
were comparable to those induced by TPA (46).
Raick found that phorbol ester tumor promoters in-
duced the appearance of "dark basal cells" in the
epidermis, whereas ethylphenylpropiolate (EPP), a
nonpromoting epidermal hyperplasic agent, did not
(41-43, 47). Wounding induced a few dark cells which
seemed to correlate with its ability to be a weak
promoter (41-43). In addition, a large number of
these dark cells are found in papillomas and carcino-
mas (42,43). Slaga et al (44,48) reported that TPA in-
duced about three to five times the number of dark
cells as mezerein which was the first major differ-
ence found between these compounds.
Inhibitors of Tumor Promotion
Various modifiers of the tumor promotion process
have been very useful in our understanding of the
mechanism(s) of tumor promotion. Table 11 lists the
potent inhibitors of mouse skin tumor promotion by
TPA. The anti-inflammatory steroid fluocinolone
acetonide (FA) was an extremely potent inhibitor of
phorbol ester tumor promotion in mouse skin (49).
Table 11. Inhibitors of phorbol ester skin tumor promotion.a
Inhibitor Reference
Anti-inflammatory steroids (55)
Cortisol
Dexamethasone
Fluocinolone acetonide
Vitamin A derivatives (55)
Combination of retinoids and anti-inflammatory
agents (55)
Protease inhibitors (55)
Tosyl lysine chloromethyl ketone (TLCK)
Tosyl arginine methyl ester (TAME)
Tosyl phenylalanine chloromethyl ketone
(TPCK)
Antipain
Leupeptin
Cyclic nucleotides (55)
Phosphodiesterase inhibitors,
isobutylmethylxanthine (IBMX) (55)
Dimethyl sulfoxide (DMSO) (55)
Butyrate, acetic acid (55)
Bacillus Calmette-Guerin (BCG) (55)
Polyriboinosinic: Polyribocytidylic acid (Poly I:C) (55)
Prostaglandin synthesis inhibitors
5,8,11,14-Eicosatetraynoic acid (ETYA)
Phenidone
Thromboxane synthetase inhibitors a
Imidazolacetophenone (R022-3581)
Imidazolphenol (R022-3582)
Phospholipase A2 inhibitor a
Dibromoacetophenone
Arachidonic acid a
Polyamine synthesis inhibitor a
Difluoromethylornithine, DFMO
Histamine a
H, receptor inhibitor a
Diphenhydramine
Butylated hydroxyanisole (BHA) a
Butylated hydroxytoluene (BHT) a
Disulfiram a
Hydroxyanisole a
aSlaga et al, unpublished results.
9Repeated applications of as little as 0.01 ,Ag almost
completely counteracted skin tumorigenesis. FA
also effectively counteracts the induced cellular pro-
liferation associated with application of phorbol
ester tumor promoters. Certain retinoids are also
potent inhibitors of mouse skin tumor promotion
(50). Verma and co-workers (50) have shown that the
retinoids that inhibit skin tumor promotion are po-
tent inhibitors of phorbol ester-induced epidermal
ODC activity. We have recently found that a combi-
nation of FA and retinoids produces an inhibitory
effect on skin tumor promotion greater than that
produced by each separately (51).
The work of Belman and Troll also indicates that
protease inhibitors cyclic nucleotides, dimethyl sulf-
oxide and butyrate also inhibit mouse skin tumor
promotion by phorbol esters (52). In addition to bu-
tyric acid, acetic acid also inhibits tumor promotion
(45,52). The phosphodiesterase inhibitor isobutyl-
methylxanthine was also found to inhibit tumor pro-
motion which gives further support to the inhibi-
tory effect of cyclic nucleotides (Slaga and Weeks,
unpublished results). Schinitsky and co-workers (53)
reported the inhibitory effect of Bacillus Calmette-
Guerin (BCG) vaccination on skin tumor promotion.
It has been shown that Poly I:C has an inhibitory ef-
fect on carcinogenesis and tumor promotion (30).
This appears to be mediated by its inhibition of pro-
moter and carcinogen induced cell proliferation (30).
Certain prostaglandin synthesis inhibitors, thromb-
oxane synthesis inhibitors and phospholipase A2 in-
hibitors also inhibit skin tumor promotion which
suggest that prostaglandins and thromboxane may
be important in tumor promotion (54). Although the
mechanism is not presently understood, arachidonic
acid at high doses is a potent inhibitor of tumor pro-
motion (54). a-Difluoromethylornithine (DFMO), a
specific inhibitor of polyamine synthesis also inhib-
its tumor promotion which suggests that poly-
amines are also important (55). The mechanism(s) by
which histamine and diphenhydramine inhibit tu-
mor promotion is currently not known (S. M.
Fischer, unpublished results). Although BHA, BHT,
disulfiram and p-hydroxyanisole are potent inhibi-
tors of skin tumor promotion by both TPA and ben-
zoyl peroxide, their mechanism of action is cur-
rently not known (T. J. Slaga, unpublished results).
It is possible that free radicals are important in tu-
mor promotion and thus these agents may prevent
promotion by their free radical-scavenging ability.
Multistage Promotion
As previously discussed, mezerein, a diterpene
similar to TPA, was capable of causing most of the
morphological and biochemical changes in skin and
Table 12. Comparison of cellular and biochemical responses
to TPA and mezreina
Relative response
TPA Mezerein
Enhancement of neoplastic phenotype 100 100
Promotion of neoplastic transformation 100 80
(C3H-10T-1/2)
Induction of epidermal cellular proliferation 50 100
Comitogenesis in lymphocytes 100 100
Inhibition of differentiation in friend 100 100
erythroleukemia cells
Stimulation of DNA synthesis 50 100
Stimulation of ODC activity 80 100
Stimulation of plasminogen activator
production 20 100
Stimulation of epidermal histidine 20 100
decarboxylase
Induction of dark basal keratinocytes 100 25
Tumor promotion 100 2
Relative binding to receptor 100 2
aFor a comparative purpose the maximum response of
mezerein or TPA is expressed as a 100. The values should
only be considered as an approximation.
in cells in culture that TPA does, but TPA was at
least 50 times more active as a tumor promoter (46).
A comparison of these TPA and mezerein responses
are shown in Table 12. Clearly, mezerein is as po-
tent or more potent than TPA. This is especially
true regarding the induction of epidermal ODC and
epidermal hyperplasia. The effect of mezerein on
ODC activity suggests that ODC induction is not a
critical event in tumor promotion (46). It should be
emphasized that this conclusion is also true for the
other morphological and biochemical responses to
mezerein.
Because of the many similarities in morphological
and biochemical responses induced by TPA and
mezerein, we felt that mezerein, although a weak
promoter, would be a good candidate as a compound
to be used in the second stage of a two-stage promo-
tion protocol as originally reported by Boutwell (4).
We recently reported that mezerein was a potent
stage II promoter (10). A summary of the results on
the use of mezerein as a second stage promoter in
two-stage promotion are shown in Table 13. As illus-
trated, TPA is about 50 times more active as a pro-
moter than mezerein. When 2,g of TPA is given
twice weekly for only 2 weeks after DMBA initia-
tion, no tumors are induced, compared to twice
weekly treatments for 18 weeks. However, when
mezerein is given at a dose of either 1, 2, 4 or 6 ig
twice weekly after the limited TPA treatment, it in-
duced a significant tumor response in a dose-depen-
dent manner. The ability of mezerein to act as a po-
tent second stage promoter was repeated in more
than 15 separate experiments (10,55,56). Also shown
in Table 13 is the ineffectiveness of EPP as a com-
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plete promoter and as a second stage promoter. In
addition, we recently found that 4-0-methyl TPA,
the calcium ionophore A23187, hydrogen peroxide
and wounding which do not promote are effective
first-stage promoters (Tables 13 and 14). These com-
pounds or wounding induce epidermal hyperplasia
and increase the number of dark basal keratino-
cytes (57). Table 14 shows some of the characteris-
tics of the first and second stages of promotion. Be-
sides showing a good dose-response for TPA as a
first stage promoter only a single application of
TPA is necessary for stage I of promotion to be ex-
pressed after repeated applications of mezerein. In
addition stage I of the promotion is partially irre-
versible for four weeks. As previously stated stage
II of promotion requires multiple applications and
also shows a good dose response with mezerein or
12-deoxyphorbol-13-2,4,6-decatrienoate (DPtri-D).
The effectiveness of some of the inhibitors of tu-
mor promotion on two-stage promotion was re-
cently reported by this laboratory (56). The effects
of FA, retinoic acid (RA), DFMO and tosyl phenylal-
anine chloromethylketone (TPCK) on two-stage pro-
motion are shown in Table 15. FA was a potent in-
hibitor of stage I and II of promotion but to a
greater degree for stage I than stage II. It should
be emphasized that only four applications of FA
with TPA were necessary to counteract the tumor
response. RA was ineffective in stage I but was a
potent inhibitor of stage II promotion whereas
TPCK specifically inhibited stage I but not stage II.
These experiments were repeated several times
and were very reproducible (55,56). Recently,
Table 14. Characteristics of the first and second stages of
tumor promotion.
Stage Characteristic
I Good dose response exists for TPA
Only one application of TPA is necessary
Partially irreversible
Four weeks can separate first and second stages of
promotion without a decrease in tumor response
There is an 80°/ decrease in tumor response if 10
weeks separate stage I and stage II of promotion
Nonpromoting agents [calcium ionophase (A23187),
4-0-methyl TPA, H202 and wounding] can act as
stage I promoters
II Good dose-response exists for mezerein
Multiple applications are required
Nonpromoting agents (DPtri-D) can act as stage II
promoters
Table 13. Two-stage promotion.a
Relative Promotion tumor
Initiation Stage I Stage II response
1 DMBA 1 wk TPA 32 times 100
2 DMBA 1 wk Mezerein (4Mg) 32 times 2
3 DMBA 1 wk TPA 4 times Acetone 28 times 0
4 DMBA 1 wk TPA 4 times Mezerein (1 Mg) 28 times 35
5 DMBA 1 wk TPA 4 times Mezerein (2 Mg) 28 times 50
6 DMBA 1 wk TPA 4 times Mezerein (4Mg) 28 times 85
7 DMBA 1 wk TPA 4 times Mezerein (6 Mg) 28 times 120
8 DMBA 1 wk 4-0-methyl TPA (80 Mg) 4 times Mezerein (2 Mg) 28 times 40
9 DMBA 1 wk TPA 4 times 4-0-methyl TPA (80Mg) 28 times 0
10 DMBA 1 wk A23187 (80 Mg) 4 times Mezerein (2 Mg) 28 times 60
11 DMBA 1 wk TPA 4 times A23187 (80Mg) 28 times 0
12 DMBA 1 wk EPP (14 mg) 32 times 1
13 DMBA 1 wk TPA 4 times EPP (14 mg) 28 times 2
aThe mice were initiated with lOnmole of DMBA and promoted with 2;g of TPA or as shown above (55).
Table 15. Effects of tumor promotion inhibitors on two-stage promotion.a
Tumor
Promotion response
Initiation Stage I Stage II (% of control)
1 DMBA 1 wk TPA 4 times Mezerein 28 times 100
2 DMBA 1 wk TPA + FA 4 times Mezerein 28 times 0
3 DMBA 1 wk TPA 4 times Mezerein + FA 28 times 20
4 DMBA 1 wk TPA + RA 4 times Mezerein 28 times 95
5 DMBA 1 wk TPA 4 times Mezerein + RA 28 times 20
6 DMBA 1 wk TPA + TPCK 4 times Mezerein 28 times 25
7 DMBA 1 wk TPA 4 times Mezerein + TPCK 28 times 94
aThe mice were initiated with 10nmole of DMBA and promoted with 2 Mg of TPA and 2Mg of mezerein. FA (1 Mg), RA (10 Mg) and
TPCK (10 Mg) were applied simultaneously with TPA or mezerein (55).
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Weeks and Slaga (unpublished results) found that
DFMO was a potent specific inhibitor of stage II
promotion.
Since the only major morphological or biochemi-
cal difference between the effects of TPA and me-
zerein on the skin is the ability of TPA to induce a
large number of dark basal keratinocytes (44,56), we
were interested in determining the effects of vari-
ous inhibitors of promotion on the appearance of
these dark cells. We reasoned that if these dark
cells are critical in the first stage of promotion and
ifFA and TPCK are potent inhibitors of stage I and
RA and DFMO of stage II, then FA and TPCK
should counteract the appearance of these cells,
whereas RA and DFMO should not. The results of
FA, RA, DFMO and TPCK on the induction of dark
basal keratinocytes by TPA are summarized in
Table 16. As hypothesized, FA and TPCK were
found effectively to counteract the appearance of
the dark cells induced by TPA, whereas RA and
DFMO had no effect (44).
Since TPCK inhibited stage I of promotion but
not stage II, and since TPCK counteracted the TPA-
induced increase in the dark basal keratinocytes but
did not have any effect on TPA-induced hyperpla-
sia, we were interested in determining the effect of
TPCK on TPA-induced ODC activity. As shown in
Table 16, TPCK had very little effect on TPA- and
mezerein-induced epidermal ODC activity.
The anti-inflammatory steroid FA not only coun-
teracted the appearance of dark cells induced by
TPA but also suppressed the hyperplasia induced
by TPA. In fact, the skins of mice treated with FA
plus TPA appeared the same as untreated skin.
This is in agreement with our previously reported
observations on the inhibitory effect of FA on TPA
induced inflammation, hyperplasia and DNA synthe-
sis (49). However, FA had little effect on the TPA
increased ODC activity (Table 16) as compared to its
effect on inhibition ofpromotion.
It is also ofinterest to point out that although RA
inhibited stage 2 of promotion, it had no inhibitory
effect on the TPA- or mezerein-induced hyperplasia
(Table 16). However, certain retinoids have been
found to be potent inhibitors of TPA- and mezerein-
induced epidermal ODC activity (46). In this regard,
DFMO is a specific irreversible inhibitor of ODC ac-
tivity. This data suggests that the induction of epi-
dermal ODC activity followed by increased poly-
amines may be important in stage II of promotion.
In this regard FA and TPCK have either no effect
or only a slight inhibitory effect on TPA or mezer-
ein induced ODC activity (55). FA does, however,
significantly decrease the TPA induced spermidine
levels in the epidermis (55,56). This effect plus FA's
inhibitory effect on TPA-induced hyperplasia may
be responsible for its inhibitory effect on stage II
promotion. Figure 2 depicts the various stages of
promotion, the important events in each stage, and
where the various inhibitors are effective.
In conclusion, skin carcinogenesis can be opera-
tionally and mechanistically divided into at least
three stages; initiation, stage I of promotion and
TWO-STAGE PROMDTION
STAGE I STAGE II
INITIATION TPA MEZEREIN
A23187
H202
4-0 METWL TPA
WOUNDING
1. INDUCTION OF 1. POLYAMINE
DARK CELLS 2. CELL PRO-
(PRIMITIVE SKIN LIFERATIO
STF;T CELLS)
2, PROSTAGLANDINS
'S f
FA
TPCK
RA
FA
DFTD
ES
A
FIGURE 2. Diagram of the various stages of skin car-
cinogenesis showing the important events in stage I and II
of promotion and where FA, RA, DFMO and TPCK inhibit
promotion.
Table 16. Effects ofFA, RA and TPCK on tumor promotion and TPA-induced epidermal hyperplasia,
dark keratinocytes and polyamine levels.
Relative ability (%) to counteracta
TPA-induced
TPA TPA-induced TPA-induced ODC and
Inhibitor promotion hyperplasia dark cells polyamine levels
FA 100 100 100 20
RA 80 0 0 85
.TPCK 70 0 70 10
DFMOb 55 0 0 95
aThe abilities of FA, RA, DFMO and TPCK to counteract the various TPA responses are expressed from 100% (complete sup-
pression) to 0% (no effect). The effects ofthe inhibitors were determined from dose-response studies (55, 56).
bWeeks and Slaga, unpublished data.
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stage 2 of promotion. Covalent binding of the initia-
tor to epidermal DNA probably in dark basal kera-
tinocytes leading to a mutation in some aspect of
differentiation appears to be important in the initia-
tion stage. The stimulation of dark basal keratino-
cytes (stem cells?) are important in stage I of pro-
motion whereas polyamines and cell proliferation
are important in stage 2 of promotion. It is not pres-
ently known if other experimental carcinogenesis
systems or the induction of human cancer go
through a series similar to that in the mouse skin.
' This research was sponsored by the Office of Health and En-
vironmental Research, U.S. Department of Energy, under con-
tract W-7405-eng-26 with the Union Carbide Corporation.
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